Ariceum Therapeutics GmbH

https://www.ariceum-therapeutics.com

LinkedIn: https://www.linkedin.com/company/ariceum-therapeutics

Ariceum Therapeutics is a private, clinical stage radiopharmaceutical company focused on the diagnosis and precision treatment of certain neuroendocrine and other aggressive, hard-to-treat cancers. The name Ariceum is an anagram of ‘Marie Curie’ whose discovery of radium and polonium have been huge contributions to finding treatments for cancer. Ariceum’s lead targeted systemic radiopharmaceutical candidate, 177Lu-satoreotide tetraxetan (“satoreotide”), is an antagonist of the somatostatin type 2 (SSTR2) receptor which is overexpressed in aggressive neuroendocrine tumours (NETs) such as small cell lung cancer (SCLC) or Merkel Cell Carcinoma (MCC), all of which have limited treatment options and poor prognosis. Satoreotide is being developed as a ‘theranostic pair’ for the combined diagnosis and targeted radionuclide treatment of these tumours. Ariceum is also developing a radiolabelled PARP-inhibitor (ATT001), currently in Phase 1 clinical development under the trial name CITADEL-123. ATT001 was part of the acquisition of Theragnostics Ltd which was closed in June 2023. Ariceum Therapeutics, launched in 2021, acquired all rights to satoreotide from Ipsen, which has remained a shareholder of the Company. Ariceum is headquartered in Berlin, with operations in Germany, Switzerland, Australia, the United Kingdom, and the United States. Ariceum is led by a highly experienced management team and supported by specialist investors including EQT Life Sciences (formerly LSP), HealthCap, Pureos Bioventures, Andera Partners, and Earlybird Venture Capital. *

	Start	2022-05-12 reorganised
	Group	Ariceum Therapeutics (Group)
	Predecessor	SatoSea Oncology GmbH
	Industry	satoreotide (177Lu-satoreotide tetraxetan)
	Industry 2	theranostics (Tx)
	Person	Rüdiger, Manfred (Ariceum Therapeutics 202206 CEO before Catalym + Affectis + Kiadis Pharma + LSP Munich)

	Region	Berlin
	Country	Germany
	Street	10 Robert-Rössle-Str. Campus Berlin-Buch, Building 79
	City	13125 Berlin
		Address record changed: 2024-01-05

Basic data	Employees	n. a.

		* Document for »About Section«: ITM Isotope Technologies Munich SE. (1/13/25). "Press Release: ITM and Ariceum Therapeutics Enter into Supply Agreement for Therapeutic Medical Radioisotope Actinium-225". Garching, Munich & Berlin.

		Record changed: 2025-01-17